Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and giving a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 21-22 September 2016.

Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Kinase Inhibitors for Cancer Immunotherapy Combinations, “Design and Development of a Novel PI3K-p110β/δ Inhibitor, KA2237 with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity” at 4:05pm on Wednesday 21 September 2016.

For more information on Karus’s presentations or for media enquiries, please contact karus@instinctif.com.